REG - hVIVO plc - Notice of Preliminary Results

hVIVOAnnouncement

08/03/2019 07:05

RNS Number : 2370S
hVIVO plc
08 March 2019
 


hVIVO plc
("hVIVO" or the "Company")
 
Notice of Preliminary Results
 
London, UK 8 March 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, will announce its preliminary financial results for the twelve months ended 31 December 2018 on Thursday 11 April 2019.
 
A presentation and webcast for analysts will be held at 9.00am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 8.45am. A webcast recording of the event will be available on the Company's website.
 
 
For further information please contact:
 



hVIVO plc








Trevor Phillips (Executive Chairman)


+44 207 756 1300




Shelley Fraser (Finance Director & Company Secretary)
Fleur Wood (EVP, Investor Relations & Communications)
 


 




Numis Securities Limited


 +44 207 260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black / Michael Burke (Corporate Broking)


















FTI Consulting








Simon Conway / Victoria Foster Mitchell


+44 203 727 1000



 
 
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORUGUQCWUPBGMM